The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2023 | ERADIC trial: preliminary results of MRD-guided ibrutinib plus venetoclax vs FCR
In this interview, Anne-Sophie Michallet, MD, Léon Bérard Center, Lyon, France, reports the preliminary findings, regarding efficacy and safety, of the Phase II ERADIC trial (NCT04010968) in the FILO (French Innovative Leukemia Organization) group, which compares a measurable residual disease (MRD)-guided combination of ibrutinib and venetoclax to standard immunochemotherapy (FCR) in patients with chronic lymphocytic leukemia (CLL). This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
